These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 26116279)

  • 21. Physiologically Based Pharmacokinetic and Absorption Modeling for Osmotic Pump Products.
    Ni Z; Talattof A; Fan J; Tsakalozou E; Sharan S; Sun D; Wen H; Zhao L; Zhang X
    AAPS J; 2017 Jul; 19(4):1045-1053. PubMed ID: 28357656
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Physiologically Based Pharmacokinetic Models Can Be Used to Predict the Unique Nonlinear Absorption Profiles of Vismodegib.
    Lin L; Wright MR; Hop CECA; Wong H
    Drug Metab Dispos; 2022 Sep; 50(9):1170-1181. PubMed ID: 35779865
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of a Population Pharmacokinetics-Based in vitro-in vivo Correlation Model for Drugs with Site-Dependent Absorption: the Acyclovir Case Study.
    Shin S; Kim TH; Lee DY; Chung SE; Lee JB; Kim DH; Shin BS
    AAPS J; 2020 Jan; 22(2):27. PubMed ID: 31938935
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of Deconvolution-Based and Absorption Modeling IVIVC for Extended Release Formulations of a BCS III Drug Development Candidate.
    Kesisoglou F; Xia B; Agrawal NG
    AAPS J; 2015 Nov; 17(6):1492-500. PubMed ID: 26290380
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel physiologically based pharmacokinetic modeling of patupilone for human pharmacokinetic predictions.
    Xia B; Heimbach T; Lin TH; He H; Wang Y; Tan E
    Cancer Chemother Pharmacol; 2012 Jun; 69(6):1567-82. PubMed ID: 22526410
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Utilizing in vitro and PBPK tools to link ADME characteristics to plasma profiles: case example nifedipine immediate release formulation.
    Wagner C; Thelen K; Willmann S; Selen A; Dressman JB
    J Pharm Sci; 2013 Sep; 102(9):3205-19. PubMed ID: 23696038
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling.
    Shono Y; Jantratid E; Janssen N; Kesisoglou F; Mao Y; Vertzoni M; Reppas C; Dressman JB
    Eur J Pharm Biopharm; 2009 Sep; 73(1):107-14. PubMed ID: 19465123
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preparation, release and pharmacokinetics of a risperidone elementary osmotic pump system.
    Gong W; Liu Y; Mei DY; Yang M; Mei XG
    Drug Dev Ind Pharm; 2015 Mar; 41(3):464-9. PubMed ID: 24400982
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Controlled release of ziprasidone solid dispersion systems from osmotic pump tablets with enhanced bioavailability in the fasted state.
    Yanfei M; Guoguang C; Lili R; Pingkai O
    Drug Dev Ind Pharm; 2015; 41(8):1353-62. PubMed ID: 25138348
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prediction of in vivo drug performance using in vitro dissolution coupled with STELLA: a study with selected drug products.
    Chakraborty S; Yadav L; Aggarwal D
    Drug Dev Ind Pharm; 2015; 41(10):1667-73. PubMed ID: 25494535
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Applications of linking PBPK and PD models to predict the impact of genotypic variability, formulation differences, differences in target binding capacity and target site drug concentrations on drug responses and variability.
    Chetty M; Rose RH; Abduljalil K; Patel N; Lu G; Cain T; Jamei M; Rostami-Hodjegan A
    Front Pharmacol; 2014; 5():258. PubMed ID: 25505415
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of an integrated in vitro-in silico PBPK (physiologically based pharmacokinetic) model to provide estimates of human bioavailability.
    Cai H; Stoner C; Reddy A; Freiwald S; Smith D; Winters R; Stankovic C; Surendran N
    Int J Pharm; 2006 Feb; 308(1-2):133-9. PubMed ID: 16352407
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Population pharmacokinetic modeling of levodropropizine: extended application to comparative analysis between commercial formulations and exploration of pharmacokinetic effects of diet.
    Jeong SH; Jang JH; Lee YB
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Jun; 397(6):4403-4418. PubMed ID: 38103059
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of a hybrid physiologically based pharmacokinetic model with drug-specific scaling factors in rat to improve prediction of human pharmacokinetics.
    Sayama H; Komura H; Kogayu M; Iwaki M
    J Pharm Sci; 2013 Nov; 102(11):4193-204. PubMed ID: 24018828
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition.
    Poulin P; Theil FP
    J Pharm Sci; 2002 May; 91(5):1358-70. PubMed ID: 11977112
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of pharmacokinetic interactions between bicyclol and co-administered drugs in rat and human liver microsomes in vitro and in rats in vivo.
    Yang S; Hu J; Li Y; Zhao Z
    Xenobiotica; 2019 Aug; 49(8):987-994. PubMed ID: 30216099
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In silico prediction of bioequivalence of Isosorbide Mononitrate tablets with different dissolution profiles using PBPK modeling and simulation.
    Zhang F; Zhou Y; Wu N; Jia R; Liu A; Liu B; Zhou Z; Hu H; Han Z; Ye X; Ding Y; He Q; Wang H
    Eur J Pharm Sci; 2021 Feb; 157():105618. PubMed ID: 33122011
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of in vitro data in developing a physiologically based pharmacokinetic model: Carbaryl as a case study.
    Yoon M; Kedderis GL; Yan GZ; Clewell HJ
    Toxicology; 2015 Jun; 332():52-66. PubMed ID: 24863738
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preclinical pharmacokinetics of TPN729MA, a novel PDE5 inhibitor, and prediction of its human pharmacokinetics using a PBPK model.
    Gao ZW; Zhu YT; Yu MM; Zan B; Liu J; Zhang YF; Chen XY; Li XN; Zhong DF
    Acta Pharmacol Sin; 2015 Dec; 36(12):1528-36. PubMed ID: 26592518
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.